1. Home
  2. DETX vs JSPR Comparison

DETX vs JSPR Comparison

Compare DETX & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Defense Holdings Ltd. Common Shares

DETX

Liberty Defense Holdings Ltd. Common Shares

N/A

Current Price

$3.27

Market Cap

20.5M

ML Signal

N/A

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$0.60

Market Cap

22.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DETX
JSPR
Founded
N/A
2018
Country
United States
United States
Employees
27
22
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.5M
22.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DETX
JSPR
Price
$3.27
$0.60
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
$15.50
AVG Volume (30 Days)
8.2K
2.2M
Earning Date
N/A
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.22
$0.32
52 Week High
$4.25
$3.14

Technical Indicators

Market Signals
Indicator
DETX
JSPR
Relative Strength Index (RSI) 25.20 47.26
Support Level N/A $0.37
Resistance Level $3.41 $1.05
Average True Range (ATR) 0.17 0.13
MACD -0.01 0.00
Stochastic Oscillator 6.43 21.09

Price Performance

Historical Comparison
DETX
JSPR

About DETX Liberty Defense Holdings Ltd. Common Shares

Liberty Defense Holdings Ltd is engaged in the development and commercialization of security detection technologies such as airports, stadiums, schools, and more. The company's Hexwave product utilizes millimeter wave technology and Advanced 3D imaging to detect concealed threats. In addition to HEXWAVE, the company has licensed High-Definition Advanced Imaging Technology (HD-AIT) for body and shoe scanning. The Company operates through three distinct segments: Corporate, HEXWAVE, and Contract. The company generates the majority of its revenue from the Contract segment. Geographically, the company generates the majority of its revenue from the United States.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Share on Social Networks: